• July 19, 2024

Exciting opportunity to design new antibody therapy using generative AI

Announced today (December 4), the agreement will combine Absci’s Integrated Drug Creation platform with AstraZeneca’s expertise in oncology, to accelerate the discovery of a potential new cancer treatment.

Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding, milestone payments, and royalties on product sales.

“AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients,” said Sean McClain, Absci founder and CEO.

“This agreement advances Absci’s goal of creating a new generation of life-changing and transformative therapeutics using its AI platform.”

Measuring millions of protein-protein interactions

The platform harnesses generative AI and a suite of scalable wet-lab technologies. The platform generates proprietary data by measuring millions of protein-protein interactions. These data are used to train Absci’s proprietary AI models and, in later iterations, to validate antibodies designed using the de novo​ AI models.

It accelerates drug discovery by completing the cycle of data collection, AI-driven design, and wet lab validation within an estimated six weeks. It aims to enhance the likelihood of successful development outcomes for biologic drug candidates by optimizing multiple drug attributes concurrently and expanding the universe of drug targets to include those previously deemed “undruggable” such as GPCRs and ion channels.

Leave a Reply

Your email address will not be published. Required fields are marked *